Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
PLoS One. 2010 Jun 1;5(6):e10917. doi: 10.1371/journal.pone.0010917.
Endothelin-1 (ET-1), a long-acting paracrine mediator, is implicated in cardiovascular diseases but clinical trials with ET-receptor antagonists were not successful in some areas. We tested whether the quasi-irreversible receptor-binding of ET-1 (i) limits reversing effects of the antagonists and (ii) can be selectively dissociated by an endogenous counterbalancing mechanism.
METHODOLOGY/PRINCIPAL FINDINGS: In isolated rat mesenteric resistance arteries, ET(A)-antagonists, endothelium-derived relaxing factors and synthetic vasodilators transiently reduced contractile effects of ET-1 but did not prevent persistent effects of the peptide. Stimuli of peri-vascular vasodilator sensory-motor nerves such as capsaicin not only reduced but also terminated long-lasting effects of ET-1. This was prevented by CGRP-receptor antagonists and was mimicked by exogenous calcitonin gene-related peptide (CGRP). Using 2-photon laser scanning microscopy in vital intact arteries, capsaicin and CGRP, but not ET(A)-antagonism, were observed to promote dissociation of pre-existing ET-1/ET(A)-receptor complexes.
Irreversible binding and activation of ET(A)-receptors by ET-1 (i) occur at an antagonist-insensitive site of the receptor and (ii) are selectively terminated by endogenously released CGRP. Hence, natural stimuli of sensory-motor nerves that stimulate release of endogenous CGRP can be considered for therapy of diseases involving ET-1.
内皮素-1(ET-1)是一种长效旁分泌介质,与心血管疾病有关,但 ET 受体拮抗剂的临床试验在某些领域并未成功。我们测试了 ET-1 的准不可逆受体结合(i)是否限制了拮抗剂的逆转作用,以及(ii)是否可以通过内源性平衡机制选择性分离。
方法/主要发现:在分离的大鼠肠系膜阻力动脉中,ET(A)拮抗剂、内皮衍生的舒张因子和合成血管扩张剂短暂降低了 ET-1 的收缩作用,但不能防止肽的持续作用。血管周围血管舒张感觉运动神经的刺激物,如辣椒素,不仅降低而且终止了 ET-1 的持久作用。这可以被 CGRP 受体拮抗剂阻止,并且可以被外源性降钙素基因相关肽(CGRP)模拟。使用活体完整动脉中的双光子激光扫描显微镜,观察到辣椒素和 CGRP 而不是 ET(A)拮抗剂促进预先存在的 ET-1/ET(A)受体复合物的解离。
ET-1 通过不可逆结合和激活 ET(A)受体(i)发生在受体的拮抗剂不敏感部位,(ii)通过内源性释放的 CGRP 选择性终止。因此,可以考虑感觉运动神经的天然刺激物来刺激内源性 CGRP 的释放,用于治疗涉及 ET-1 的疾病。